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Abstract 35 
Our objective was to define the prevalence and clinical features of genetic Parkinson’s disease in 36 
a large UK population-based cohort, the largest multicentre prospective clinico-genetic incident 37 
study in the world. We collected demographic data, Movement Disorder Society Parkinson’s 38 
Disease Rating Scale scores, and Montreal Cognitive Assessment scores. We analysed mutations 39 
in PRKN (parkin), PINK1, LRRK2 and SNCA in relation to age at symptom onset, family history 40 
and clinical features. 41 
2,262 participants were recruited to the Tracking Parkinson’s study. 424 had young-onset 42 
Parkinson’s disease (age at onset ≤ 50) and 1,799 had late onset Parkinson’s disease. 2005 43 
patients were genotyped with a range of methods. 302 young-onset patients were fully genotyped 44 
with Multiplex Ligation-dependent Probe Amplification and either Sanger and/or exome 45 
sequencing. 1701 late-onset patients were genotyped with the LRRK2 ‘Kompetitive’ allele-46 
specific polymerase chain reaction assay and/or exome sequencing. We identified 29 (1.4%) 47 
patients carrying pathogenic mutations. 18 patients carried the G2019S or R1441C mutations in 48 
LRRK2, and one patient carried a heterozygous duplication in SNCA. In PRKN, we identified 49 
patients carrying deletions of exons 1, 4 and 5, P113Xfs, R275W, G430D and R33X. In PINK1, 50 
2 patients carried deletions in exon 1 and 5, and the W90Xfs point mutation. 51 
Eighteen percent of patients with age at onset ≤ 30 and 7.4% of patients from large dominant 52 
families carried pathogenic Mendelian gene mutations. Of all young-onset patients, 10 (3.3%) 53 
carried bi-allelic mutations in PRKN or PINK1. Across the whole cohort, 18 patients (0.9%) 54 
carried pathogenic LRRK2 mutations and one (0.05%) carried a SNCA duplication. There is a 55 
significant burden of LRRK2 G2019S in patients with both apparently sporadic and familial 56 
disease. In young-onset patients, dominant and recessive mutations were equally common. There 57 
were no differences in clinical features between LRRK2 carriers and non-carriers.  However, we 58 
did find that PRKN and PINK1 mutation carriers have distinctive clinical features compared to 59 
early onset non-carriers, with more postural symptoms at diagnosis and less cognitive 60 
impairment, after adjusting for age and disease duration. This supports the idea that there is a 61 
distinct clinical profile of PRKN and PINK1-related Parkinson’s disease.  62 
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We estimate that there are approaching 1000 patients with a known genetic aetiology in the UK 63 
Parkinson’s disease population. A small but significant number of patients carry causal variants 64 
in LRRK2, SNCA, PRKN and PINK1 that could potentially be targeted by new therapies, such as 65 
LRRK2 inhibitors. 66 
  67 
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INTRODUCTION 68 
Parkinson’s disease is a progressive neurological condition which affects 140/100,000 people 69 
within the UK (Wickremaratchi et al., 2009a). It is caused by genetic mutations in LRRK2, 70 
SNCA, PRKN (Parkin or PARK2), and PINK1 in up to 10% of patients (Lesage and Brice, 2012; 71 
Puschmann, 2013; Lubbe and Morris, 2014). These genetic factors also influence clinical 72 
features of the disease, such as age at onset (AAO) (Cilia et al., n.d.; Clark et al., 2007; Golub et 73 
al., 2009; Lesage and Brice, 2012; Klebe et al., 2013), motor features, presenting symptoms, 74 
disease progression (Davis et al., 2016) and cognition (Alcalay et al., 2012; Mata et al., 2015; 75 
Crosiers et al., 2016). 76 
Many previous studies have focussed on highly selected cohorts recruited from specialist clinics. 77 
This is likely to lead to bias both in estimates of frequency and clinical characteristics associated 78 
with specific genetic mutations. 79 
In order to overcome these issues, we designed the Tracking Parkinson’s study, a large-scale 80 
population-based prospective cohort study of recently diagnosed and early onset Parkinson’s 81 
disease patients in the UK. It is the largest single cohort study of genetic mutations in 82 
Parkinson’s disease and is relatively unbiased. Analysis of this cohort is important to: i.) develop 83 
more accurate estimates of genetic risk and the likelihood of a known genetic cause overall and 84 
in specific patient sub-groups; ii.) estimate the likelihood of further high risk genes that have not 85 
yet been identified and iii.) understand the contribution of Mendelian gene variation to the 86 
phenotype of Parkinson’s disease.   87 
Several studies have examined the frequency of gene mutations in early onset Parkinson’s 88 
disease patients (Alcalay et al., 2010a; Kilarski et al., 2012). However, some mutations, such as 89 
LRRK2, are also present at a significant rate in non-familial late onset Parkinson’s disease 90 
patients (Clark et al., 2006a). Previous studies have also sometimes used single techniques such 91 
as partial Sanger sequencing, which are not able to detect copy number variation common in 92 
PRKN and less common point mutations. In our analysis, mutations were comprehensively 93 
identified using a range of different genetic screening methods, including whole-exome 94 
sequencing, Multiplex Ligation-dependent Probe Amplification (MLPA) and Sanger sequencing. 95 
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The aim of this study is to describe the frequency of pathogenic Mendelian gene variants in the 96 
general Parkinson’s disease population and in specific disease sub-groups. In addition, we sought 97 
to understand the relationship between Mendelian mutations and clinical phenotype at 98 
presentation. 99 
METHODS 100 
Patients were recruited to the Tracking Parkinson’s study from sites across the UK. Patients 101 
were required to have a clinical diagnosis of Parkinson’s disease fulfilling Queen Square Brain 102 
Bank criteria (Hughes et al., 2001). This project was funded by Parkinson’s UK and supported 103 
by the National Institute for Health Research.  104 
Patients with disease duration of less than 3.5 years at time of diagnosis were recruited as ‘recent 105 
onset’ participants. Patients with disease duration of greater than 3.5 years at time of diagnosis 106 
and AAO ≤ 50 years were recruited as ‘established young onset’ participants. Patients were 107 
recruited regardless of ethnicity, including Jewish ethnicity. Full eligibility criteria, exclusion 108 
criteria and methods of recruitment have been described previously (Malek et al., 2015b). 109 
Importantly, unlike most studies of this type, patients were recruited irrespective of any prior 110 
information on genetic status.  111 
Participants’ motor features and non-motor features were assessed using standardised and 112 
validated scales, including the Movement Disorder Society Unified Parkinson’s Disease Rating 113 
Scale (MDS-UPDRS), Hoehn and Yahr stage and Montreal Cognitive Assessment (MoCA). Full 114 
details are provided in the Supplementary Methods. 115 
Pathogenic mutations in the studied genes were defined according to MDSGene 116 
(http://www.mdsgene.org) (Lill et al., 2016; Kasten et al., 2018), and the Parkinson Disease 117 
Mutation Database (PDmutDB; http://www.molgen.vib-ua.be/Parkinson’s diseaseMutDB/). 118 
Variants that did not meet pathogenicity criteria according to MDSGene (variants classified as 119 
‘benign’) were not reported. 120 
Genetic analysis of Parkinson’s disease gene mutations 121 
At study entry, blood samples were collected from every participant and DNA was extracted 122 
from an ethylene diamine tetraacetic acid sample. We screened for mutations in PRKN, PINK1 123 
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and GBA with Sanger sequencing. As GBA is considered a risk gene for Parkinson’s rather than a 124 
pathogenic single gene cause, we reported the results of GBA sequencing separately (Malek et 125 
al., 2018). 126 
Whole exome sequencing was performed in a subset of young-onset and familial patients 127 
(N=489) (see Supplementary Methods). Exome sequencing data was screened for pathogenic 128 
variants in SNCA, LRR2K2, PRKN, PINK1, DJ-1 and VPS35. 129 
Genotyping in young-onset and late-onset patients 130 
2106 patients with Parkinson’s disease were genotyped for the LRRK2 G2019S mutation using 131 
the ‘Kompetitive’ allele-specific polymerase chain reaction (KASP) assay (LGC Genomic 132 
Solutions).  133 
We performed SNP array genotyping for 2116 samples. Samples were genotyped using the 134 
Illumina HumanCore Exome array supplemented with custom content, including over 27,000 135 
custom variants that have been previously implicated in neurological, neurodegenerative and 136 
psychiatric conditions (Malek et al., 2015b). For imputation, genotypes were aligned to the 1000 137 
Genomes Phase 3 v5 mixed population reference panel (Auton et al., 2015) (build hg19/ 138 
GRCh37) and imputed using Minimac3 (Das et al., 2016) on the Michigan Imputation Server 139 
(see Supplementary Methods). 140 
Genotyping in young-onset patients 141 
Patients with AAO ≤ 50 were screened for point mutations in PRKN and PINK1 using Sanger 142 
sequencing (Figure 2). We also performed MLPA to detect and confirm copy number variation 143 
in PRKN, PINK1, DJ1 and SNCA. MLPA was performed with the MRC Holland SALSA MLPA 144 
P051 Parkinson kit (version D1), according to the manufacturer’s instructions. Of 424 patients, 145 
291 (68.7%) were successfully genotyped for PRKN and PINK1 with both MLPA and Sanger 146 
sequencing. Eleven patients were screened for copy number variants using MLPA but were not 147 
Sanger sequenced. Exome sequencing was performed in 269 patients.  148 
For our final phenotype-genotype analyses, we included young-onset patients if MLPA had been 149 
completed, and either Sanger sequencing or exome sequencing, or both, had been completed. 150 
The combination of these methods was selected in order to detect both copy number variants and 151 
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point mutations in PRKN and PINK1. In total, 302 patients with AAO ≤ 50 were included for 152 
final analysis. 153 
Genotyping in late-onset patients 154 
Exome sequencing was performed in 219 late-onset patients with a positive family history of 155 
Parkinson’s disease and 1 patient with missing AAO and a positive family history. 156 
In late-onset patients with 2 or more additional family members affected by Parkinson’s disease, 157 
MLPA was performed in 65 of 74 (87.8%) patients. 158 
For the final phenotype-genotype analyses, we included late-onset patients if either LRRK2 159 
KASP genotyping or exome sequencing had been successfully completed. In total, 1701 late-160 
onset patients were included for final analysis, as well as 2 patients with missing AAO. 161 
In total, 2005 patients with Parkinson’s disease were included for final analysis (302 young-162 
onset, 1701 late-onset, 2 missing AAO).  163 
Mutations of uncertain pathogenicity 164 
From the exome sequencing data, we report on the frequency of variants that have been 165 
previously reported in Parkinson’s disease or parkinsonism but whose pathogenicity is uncertain 166 
(see Supplementary Methods and Supplementary Table 4).  167 
This study was not designed to confirm pathogenicity of variants through segregation or 168 
comparison of allele frequencies in cases and controls. However, we report allele frequencies in 169 
our cohort from exome sequencing alongside allele frequencies in controls obtained from 170 
gnomAD (http://gnomad.broadinstitute.org/).  171 
Haplotype and relatedness analysis 172 
Unimputed genotype data were used for pairwise identity-by-descent (IBD) analysis. Imputed 173 
genotype data were used for haplotype analysis. Individual haplotypes were constructed 174 
manually for mutation carriers. The markers used to construct haplotypes are detailed in the 175 
Supplementary Materials.   176 
Statistical analyses 177 
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Demographic characteristics were compared using t-tests, Fisher’s exact tests for proportions, or 178 
two-sample proportion tests. Linear regression was used for comparisons of demographic 179 
characteristics with covariate adjustment. To assess the association between clinical outcomes 180 
and genetic status, we used linear regressions of continuous scores against gene status (mutation 181 
positive or mutation negative) adjusting for age at assessment, disease duration at study entry, 182 
sex and LEDD.  Hoehn and Yahr stage, MoCA subdomain and dystonia comparisons were 183 
conducted using ordered logistic regression. Motor subtype was analysed using multinomial 184 
logistic regression with the tremor dominant group as the comparator. All p-values were 2-tailed. 185 
We applied the Bonferroni correction for multiple testing for the number of independent tests in 186 
Table 5 and 7. Statistical analysis was conducted using STATA (version 14, StataCorp, Texas, 187 
USA) and R (version 3.5.1). 188 
Prevalence estimates 189 
We estimated the absolute numbers of Parkinson’s disease patients with a Mendelian genetic 190 
cause in the UK using the following approach. We used age-specific prevalence rates from a 191 
previous UK meta-analysis (Wickremaratchi et al., 2009b) and applied the rates to the Office of 192 
National Statistics Great Britain mid-2016 population estimates (Office for National Statistics, 193 
2017) to derive an approximate number of all Parkinson’s disease patients. The age distribution 194 
of the Parkinson’s disease population (as a percentage) was used to standardise the rates of 195 
genetic Parkinson’s disease within our cohort (per 100,000).  From this, we derived the new age-196 
standardised rate of genetic Parkinson’s disease. We applied this age-standardisation method 197 
because our over-sampling of young onset cases has resulted in a non-representative age-198 
distribution of patients. This new rate was then applied to the total Parkinson’s disease 199 
population to estimate the absolute number of patients with a Mendelian genetic cause in the UK 200 
population. It is important to note that as we have derived the rates from our incident cases 201 
(excluded established young onset cases), we have assumed that the rates are representative of all 202 
prevalent cases. This may not be true if these Mendelian forms of Parkinson’s disease are 203 
associated with better or worse survival, in which case our estimates will be either an under- or 204 
over-estimate of the true numbers. 95% confidence intervals were calculated using the Poisson 205 
distribution. 206 
 207 
              Mendelian Parkinson’s disease in a large UK cohort.   10/48 
Data availability 208 
The anonymised data from this study are available to researchers, to support other studies. Please 209 
apply via the Tracking Parkinson’s project coordinator (tracking-parkinsons@glasgow.ac.uk). 210 
RESULTS 211 
Table 1 shows the baseline demographics for participants that met Parkinson’s disease diagnostic 212 
criteria. Data are presented separately for three groups below, according to inclusion criteria for 213 
recruitment. Young onset patients were separated into recent and established patients, as only the 214 
recent onset patients represent an incident, largely population-based cohort of Parkinson’s 215 
disease. For this reason, only recent onset patients were used to estimate the prevalence of 216 
genetic forms of Parkinson’s disease in the UK. 217 
1) Recent late onset Parkinson’s disease patients (AAO > 50, disease duration ≤ 3.5 years at 218 
time of diagnosis),  219 
2) Recent young onset Parkinson’s disease patients (AAO ≤ 50, disease duration ≤ 3.5 years 220 
at time of diagnosis)  221 
3) Established young onset Parkinson’s disease patients (AAO ≤ 50, disease duration > 3.5 222 
years at time of diagnosis). 223 
37 patients received a revised alternative diagnosis other than Parkinson’s disease or had 224 
conflicting dopamine transporter (DaT) scan results and were excluded from further analysis. On 225 
rare occasions, LRRK2 mutations may be present in progressive supranuclear palsy or atypical 226 
parkinsonian patients (Sanchez-Contreras et al., 2017; Vilas et al., 2017), however we did not 227 
identify any pathogenic mutations in these patients.  228 
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Table 1. Baseline demographics for all Parkinson’s disease patients with known AAO.  229 
 Recent, late onset 
patients 
(AAO>50, ≤3.5 
years from 
diagnosis) 
 N=1799 
Recent, young 
onset patients 
(AAO≤50, ≤3.5 
years from 
diagnosis) N=197 
Established young 
onset patients  
(AAO≤50, >3.5 
years from 
diagnosis) 
N=227 
Total 
N=2223 
Age at recruitment (years)  69.3 (7.5) 48.8 (6.2) 54.5 (7.7) 66.0 (10.2) 
Age at onset (years) 66.4 (7.7) 43.7 (5.6) 41.1 (7.1) 61.8 (12.1) 
Disease duration at 
diagnosis (years) 
1.3 (0.9) 1.4 (1.0) 11.4 (6.4) 2.4 (3.8) 
Disease duration at entry 
(years) 
2.9 (2.1) 5.2 (6.6) 13.1 (7.4) 4.0 (4.6) 
Family history (n, (%)) 
No family history 1442 (80.2%) 145 (73.6%) 166 (73.1%) 1753 (78.9%) 
1 additional affected 
family member 
267 (14.8%) 
 
41 (20.8%) 47 (20.7%) 355 (16.0%) 
 
2 additional affected 
family members 
59 (3.3%) 8 (4.1%) 8 (3.5%) 75 (3.4%) 
3 additional affected 
family members 
11 (0.6%) 2 (1.0%) 4 (1.8%) 17 (0.8%) 
4 or more additional 
affected family members 
4 (0.2%) 0 (0.0%) 1 (0.4%) 5 (0.2%) 
Consistent with dominant 
inheritance  
305 (17.0%) 
 
49 (24.9%) 57 (25.1%) 411 (18.5%) 
Consistent with recessive 
inheritance  
36 (2.0%) 
 
2 (1.0%) 
 
3 (1.3%) 41 (1.8%) 
Consanguinity 
Non-consanguineous 1741 (96.8%) 191 (97.0%) 220 (96.9%) 2152 (96.8%) 
Consanguineous 16 (0.9%) 2 (1.0%) 2 (0.9%) 20 (0.9%) 
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Ethnicity 
White 1742 (96.8%) 188 (95.4%) 211 (93.0%) 2141 (96.3%) 
Asian or Asian British 16 (0.9%) 3 (1.5%) 8 (3.5%) 27 (1.2%) 
Black or Black British 10 (0.6%) 3 (1.5%) 2 (0.9%) 15 (0.7%) 
Chinese 0 (0.0%) 0 (0.0%) 2 (0.9%) 2 (0.1%) 
Mixed 4 (0.2%) 0 (0.0%) 0 (0.0%) 4 (0.2%) 
Other 2 (0.1%) 1 (0.5%) 0 (0.0%) 3 (0.1%) 
Sex     
Male 1181 (65.7%) 124 (62.9%) 149 (65.6%) 1454 (65.4%) 
AAO= age at onset 230 
Consistent with dominant inheritance=family members from multiple generations affected 231 
Consistent with recessive inheritance=family members only from the same generation affected  232 
 233 
Summary of genotyping 234 
Supplementary Figures 1 to 5 show the number of patients that were genotyped for each method. 235 
The shaded boxes highlight the samples that were included for analysis. There were 236 
approximately 100 patients for which DNA was not available for genotyping (this varied 237 
between different methods). These patients were excluded from phenotype-genotype analyses. 238 
For young-onset patients, we included samples for final analysis if MLPA had been completed, 239 
and either Sanger sequencing or exome sequencing or both had been successfully completed. In 240 
total, 302 patients with AAO ≤ 50 were included for final analysis of PRKN and PINK1. 241 
For late-onset patients, we included patients for final analysis if the samples had been genotyped 242 
with the LRRK2 KASP assay for G2019S, and/or exome sequencing. In total, 1701 late-onset 243 
patients were included for final analysis, as well as 2 patients with missing AAO. 244 
In total, 2005 patients with Parkinson’s disease were included for final analysis (302 young-245 
onset, 1701 late-onset, 2 missing AAO).  246 
 247 
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Summary of mutations identified  248 
We identified 14 different pathogenic mutations in LRRK2, SNCA, PRKN and PINK1 in 29 out 249 
of 2005 patients (1.4%, 95% CI 0.9-2.0%) (Tables 2 and 3). This estimate is conservative as not 250 
all samples were comprehensively tested, therefore the true mutation rate may be higher. 251 
18 patients carried a mutation in LRRK2, 1 patient carried a SNCA mutation, 8 patients carried 252 
biallelic PRKN mutations and 2 patients carried biallelic PINK1 mutations. No patients were 253 
found carrying pathogenic mutations in VPS35 or DJ1. No patient carried pathogenic mutations 254 
in more than one gene. 3 patients carried the LRRK2 G2019S mutation and additionally one or 255 
more mutations in GBA (p.E326K and p.P122H). The mean AAO for patients carrying mutations 256 
in both LRRK2 and GBA mutations was 43.2 years (SD=5.1), compared to an AAO of 56.5 years 257 
(SD=12.9) for LRRK2 mutation carriers without GBA mutations. Pathogenic mutation carriers 258 
are shown in Supplementary Table 1 and the list of unique mutations are shown in 259 
Supplementary Table 2. 260 
We identified 9 patients carrying single heterozygous pathogenic mutations in PRKN and PINK1 261 
(Supplementary Table 3). Previous analysis of this cohort showed no differences between 262 
carriers of single heterozygous PRKN mutations (including mutations of uncertain pathogenicity) 263 
and non-carriers other than in olfaction (Malek et al., 2015a), therefore patients with single 264 
heterozygous mutations in recessive genes were analysed as non-carriers. 265 
One patient carried 3 pathogenic mutations in PRKN (Supplementary Table 1). 266 
Mutations were common in patients with very young onset and patients with multiple family 267 
members also affected by Parkinson’s disease. 18.8% (3/16; 95% CI 6.6 – 43.0%) of Parkinson’s 268 
disease patients with onset ≤ 30 carried pathogenic mutations. In young-onset patients, 18.2% 269 
(4/22; 95% CI 7.3 – 38.5%) of patients with 2 or more additional affected family members 270 
carried pathogenic mutations. In late-onset patients, 4.2% (3/72; 95% CI 1.4-11.5%) of patients 271 
with 2 or more additional affected family members carried pathogenic mutations.   272 
Notably, the LRRK2 G2019S mutation was more common in young onset patients (2.2%, 9/408; 273 
95% CI 0.7 – 3.6%) than in later onset patients (0.4%, 7/1701; 95% CI 0.1 – 0.7%), p=0.001 274 
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(Fisher’s exact test, OR = 5.5, 95% CI 1.8-17.3). In addition, early onset patients were equally 275 
likely to have recessive (2.5%, 10/408) and dominant pathogenic mutations (2.2%, 9/408). 276 
Pathogenic mutations were only identified in patients reporting ‘White’ ethnicity (N=2005 277 
genotyped).  278 
IBD analysis was conducted based on 25,781 SNPs in linkage equilibrium. This showed that 279 
none of the mutation carriers were related to each other (pi-hat <0.1 for all, indicating no closer 280 
relations than third-degree relatives).  281 
Constructed haplotypes and the results of haplotype analysis are shown in the Supplementary 282 
Materials (Supplementary Figures 6 to 9).  283 
  284 
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Table 2. Overall frequency of dominant gene mutation carriers for known pathogenic variants in 285 
successfully genotyped patients. Percentages and 95% CIs are shown in brackets. 286 
 Young onset N=408 Late onset N=1701 All N=2003 
LRRK2 9 (2.2%; 0.8-3.6%) 9 (0.5%; 0.2-0.9%) 18 (0.9%; 0.5-1.3%) 
SNCA 0 (0%; 0.0 – 0.9%) 1 (0.06%; 0.01-0.3%) 1 (0.05%; 0.04-0.1%) 
All autosomal 
dominant (LRRK2 
and SNCA) 
9 (2.2%; 0.8-3.6%) 10 (0.6%; 0.2-1.0%) 19 (0.9%; 0.5-1.4%) 
 287 
Table 3. Overall frequency of biallelic recessive gene mutation carriers for known pathogenic 288 
variants in successfully genotyped young onset patients (AAO ≤ 50). Percentages and 95% CIs 289 
are shown in brackets. 290 
PRKN Young onset N = 302 
Homozygous 0 (0%; 0.0-0.1.3%) 
Compound heterozygous 8 (2.6%; 0.8-4.5%) 
PINK1  
Homozygous 1 (0.3%; 0.06-1.9%) 
Compound heterozygous 1 (0.3%; 0.06-1.9%) 
All autosomal recessive (PRKN and 
PINK1 biallelic mutations) 
10 (3.3%; 1.3-5.3%) 
 291 
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Table 4. Rate of known dominant pathogenic mutations based on clinical presentation. 292 
 LRRK2 
N=18 
SNCA 
N=1 
Rate of all 
pathogenic dominant 
mutations 
Age at onset    
≤20 years (N=4) 0/4 (0%) 0/4 (0%) 0/4 (0%) 
≤30 years (N=18) 0/18 (0%) 0/18 (0%) 0/18 (0%) 
≤40 years (N=118) 2/118 (1.7%) 0/118 (0%) 2/118 (1.7%) 
≤50 years (N=408) 9/408 (2.2%) 0/408 (0%) 9/408 (2.2%) 
≤60 years (N=784) 10/784 (1.3%) 1/784 (0.1%) 11/784 (1.4%) 
≤70 years (N=1552) 17/1552 (1.1%) 1/1552 (0.06%) 18/1552 (1.2%) 
≤80 years (N=2050) 18/2050 (0.9%) 1/2050 (0.05%) 19/2050 (0.9%) 
All (N=2109) 18/2109 (0.9%) 1/2109 (0.05%) 19/2109 (0.9%) 
Mean age of onset in years (SD) 54.3 (12.9)  54.1 (12.6) 
Family history    
No other family members 
affected 
8/1658 (0.5%) 0/1658 (0%) 8/1658 (0.5%) 
1 other family member affected 7/344 (2.0%) 0/344 (0%) 7/344 (2.0%) 
2 other family members affected 1/72 (1.4%) 1/72 (1.4%) 2/72 (2.8%) 
3 other family members affected 2/17 (11.8%) 0/17 (0%) 2/17 (11.8%) 
4 or more family members 
affected 
0/5 (0%) 0/5 (0%) 0/5 (0%) 
 293 
LRRK2 294 
We identified 18 patients carrying heterozygous LRRK2 mutations, either G2019S (N=16) or 295 
R1441C (N=2). 55.6% (10/18) carriers reported a positive family history of Parkinson’s disease.  296 
 297 
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Both LRRK2 R1441C carriers reported a family history of Parkinson’s disease. As we only 298 
screened for the R1441C mutation through exome sequencing in familial and/or young-onset 299 
patients, our results for R1441C cannot be used to compare familial vs. non-familial patients.  300 
 We only included LRRK2 G2019S mutation carriers for our analysis of family history. G2019S 301 
mutations were more common among patients with a positive family history (1.9%, 95% CI 0.5-302 
3.1%) than patients without a family history of Parkinson’s disease (0.5%, 95% CI 0.1-0.8%), 303 
p=0.009 (Fisher’s exact test, OR = 3.9, 95% CI 1.3-11.8). However, within the G2019S carriers, 304 
50% had a positive family history and 50% did not have a family history of Parkinson’s (50%, 305 
95% CI 25.5-74.5%). 306 
LRRK2 mutation carriers (G2019S and R1441C carriers together) had an earlier mean AAO 307 
(54.3 years, 95% CI 47.9-60.7) compared to non-carriers (61.7 years, 95% CI 61.2-62.2; 308 
p=0.01). AAO for LRRK2 carriers ranged from 35.2 to 78.7 years. LRRK2 mutations were more 309 
frequent in early onset (2.2%, 95% CI 1.0-4.2%) compared to late onset patients (0.5%, 95% CI 310 
0.2-1.0%), p=0.003 (Fisher’s exact test, OR = 4.2, 95% CI = 1.5-12.1).  311 
Clinical features of LRRK2 carriers compared to non-carriers are presented in Table 5 (excluding 312 
patients with recessive gene mutations). We did not include the SNCA carrier in this analysis 313 
given that previous literature suggests that LRRK2 and SNCA mutation carriers have different 314 
clinical features (Trinh et al., 2018). We did not find any differences in clinical features between 315 
LRRK2 carriers and non-carriers.  316 
SNCA 317 
SNCA copy number variants were screened with MLPA in 65 patients with familial Parkinson’s 318 
disease with 2 or more family members affected. One patient (1.5%) carried a heterozygous 319 
whole gene duplication was identified, who reported 2 additional family members affected by 320 
Parkinson’s disease. We were unable to compare the clinical features of SNCA carriers to non-321 
carriers given that only one SNCA carrier was identified.   322 
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Table 5. Comparison of motor features, fluctuations and non-motor features by LRRK2 mutation status (LRRK2 carriers vs. non-323 
carriers). Patients carrying biallelic recessive mutations and one patient carrying a SNCA mutation were excluded from analyses. 324 
Scores in the first 2 columns are means (SD), except for Hoehn and Yahr stage, symptoms present at diagnosis and motor subtype 325 
which are shown as N or proportions (%). Increasing scores and increasing beta values for motor and non-motor variables are 326 
associated with worse symptoms, with the exception of the MoCA test scores. Increasing scores and increasing beta values for the 327 
MoCA test are associated with better cognition.  328 
Variable Mutation negative 
N=2082 
LRRK2 positive 
N=18 
Beta (95% CI) 
LRRK2 carriers vs. non-
carriers 
p-valuea 
Age at entry (years) 66.0 (10.1) 60.1 (10.4) -5.2 (-9.9, -0.5) 0.030b 
Age at onset (years) 61.8 (11.9) 54.3 (12.9) -5.2 (-9.9, -0.5) 0.030b 
Disease duration (years) 4.0 (4.4) 5.2 (4.5) 0.7 (-1.3, 2.8) 0.482c 
Delay to diagnosis (time from 
symptom onset to diagnosis) (years) 
1.8 (2.9) 1.5 (1.3) -0.4 (-1.8, 1.0) 0.580c 
Motor features     
MDS-UPDRS III total score 23.4 (12.7) 28.6 (15.2) 6.7 (0.1, 13.3) 0.047 
Severity score MDS-UPDRS-III/years 
from symptom onset 
10.4 (11.8) 9.4 (7.3) 0.6 (-5.7, 6.8) 0.862d 
Upper limb score (max 56) 10.7 (6.3) 12.1 (6.3) 2.1 (-0.9, 5.1) 0.163 
Lower limb score (max 32) 5.1 (3.9) 6.8 (5.5) 1.7 (-0.2, 3.6) 0.085 
Gait and freezing (max 8) 1.1 (1.1) 1.6 (1.7) 0.4 (-0.1, 0.9) 0.097 
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Hoehn and Yahr stage   0.3 (-0.7, 1.2) 0.595 
0-1.5 (%) 950 (46.0%) 7 (38.9%)   
2 or 2.5 (%) 957 (46.3%) 10 (55.6%)   
3+ (%) 160 (7.7%) 1 (5.6%)   
Symptoms present at diagnosis     
Tremor 1499/2017 (74.3%) 13/18 (72.2%) 0.3 (-0.8, 1.6) 0.586 
Rigidity 1410/1925 (73.2%) 13/18 (72.2%) -0.08 (-1.2, 1.2) 0.891 
Bradykinesia 1554/1966 (79.0%) 12/18 (66.7%) -0.8 (-1.8, 0.3) 0.121 
Postural problems 363/1898 (19.1%) 4/18 (22.2%) 0.009 (-1.5, 1.2) 0.989 
Other 456/1827 (25.0%) 4/16 (25 %) 0.2 (-1.1, 1.3) 0.731 
Motor subtype     
Tremor dominant 835/1892  (44.1%) 7/17 (41.2%)   
Non-tremor dominant (PIGD) 813/1892 (43.0%) 10/17 (58.8%) -2.8 (-0.5, 1.8) 0.246 
Mixed 244/1892 (12.9%) 0/17 (0%) -8.7 (NA)* NA* 
Motor complications     
MDS-UPDRS-IV total score 1.3 (2.8) 2.8 (3.3) 0.1 (-0.9, 1.2) 0.794 
Dyskinesias (MDS-UPDRS IV part 1 
and 2 sum - max 8) 
0.3 (1.0) 0.4 (0.9) -0.2 (-0.5, 0.1) 0.259 
Fluctuations (MDS-UPDRS IV part 3, 
4 and 5 sum - max 12) 
0.9 (1.9) 2.1 (2.6) 0.3 (-0.4, 1.1) 0.408 
Dystonia (max 4) 0.2 (0.6) 0.3 (0.6) 0.01 (-0.2, 0.3) 0.915 
Non-motor features     
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Cognition - total MoCA score 25.2 (3.5) 25.4 (3.2) -0.2 (-1.9, 1.4) 0.761 
Visuospatial (max 5) 4.3 (1.1) 4.2 (1.2) -0.2 (-0.7, 0.3) 0.359 
Naming (max 3) 2.9 (0.3) 2.9 (0.3) -0.05 (-0.2, 0.1) 0.535 
Attention (max 6) 5.2 (1.0) 5.3 (0.8) 0.1 (-0.4, 0.6) 0.690 
Language (max 3) 2.4 (0.8) 2.4 (0.7) -0.03 (-0.4, 0.3) 0.865 
Abstraction (max 2) 1.6 (0.6) 1.7 (0.7) 0.003 (-0.3, 0.3) 0.983 
Recall (max 5) 2.7 (1.6) 2.9 (1.8) 0.05 (-0.7, 0.8) 0.898 
Orientation (max 6) 5.8 (0.5) 5.8 (0.5) -0.03 (-0.2, 0.2) 0.756 
LADS Anxiety score (max 18) 4.5 (3.8) 5.8 (3.8) 0.9 (-0.8, 2.6) 0.287 
LADS Depression score (max 18) 4.5 (3.3) 5.1 (3.3) 0.3 (-1.2, 1.8) 0.706 
Sleep disturbance (ESS score) 7.1 (4.8) 9.7 (6.8) 1.6 (-0.7, 3.8) 0.173 
REM Sleep Behaviour Disorder 
(RBDSQ) scale score 
4.8 (3.2) 6.4 (3.5) 1.0 (-0.5, 2.5) 0.191 
Autonomic function: SCOPA total 
score 
9.3 (5.8) 10.8 (6.4) 2.6 (-1.1, 6.3) 0.170 
SD = standard deviation; CI = confidence interval; MDS-UPDRS = Movement Disorder Society Unified Parkinson’s Disease Rating 329 
Scale; PIGD = postural instability gait difficulty; MoCA= Montreal Cognitive Assessment; LADS = Leeds Anxiety and Depression 330 
Scale; ESS= Epworth Sleep Scale; RBDSQ = Rapid Eye Movement Sleep Behaviour Disorder Screening Questionnaire; SCOPA 331 
= SCales for Outcomes in PArkinson's disease. 332 
a P value of clinical features of LRRK2 carriers together compared to non-carriers, excluding patients with recessive gene mutations 333 
and one patient with SNCA mutation. Adjusting for age at entry, gender, disease duration at entry/assessment and LEDD total, unless 334 
otherwise specified. 335 
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b Adjusting for gender and disease duration at entry 336 
c Adjusting for gender and age at entry. 337 
d Adjusting for age, gender and LEDD total. 338 
*Insufficient count to fit model339 
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Young-onset patients 340 
We identified 19/302 (6.3%) young-onset patients carrying pathogenic mutations in both 341 
dominant and recessive genes. The proportions of mutation carriers by AAO and family history 342 
are presented in Table 6. Recessive gene mutation carriers had an earlier mean AAO (32.7 years) 343 
compared to non-carriers (41.1 years), p<0.001, excluding dominant mutation carriers. 344 
When considering all young-onset mutation carriers (PRKN, PINK1, LRRK2 and SNCA) 345 
mutation carriers, the mean AAO was also younger than non-carriers (37.5 vs. 41.1 years; 346 
p=0.02). Mutations were more frequent in patients with a positive family history (11.0%) than in 347 
patients with no family history of Parkinson’s disease (4.2%), p=0.04 (Fisher’s exact test, OR = 348 
2.8, 95% CI 1.0-8.1). 349 
  350 
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Table 6. Cumulative rate of pathogenic mutations based on clinical presentation in successfully 351 
genotyped early onset Parkinson’s disease patients (AAO ≤ 50), N=302. 352 
 PINK1 
(biallelic) 
N=2 
PRKN 
(biallelic) 
N=8 
All recessive 
gene mutations 
N=10 
Age at onset    
≤20 years (N=4) 0/4 (0%) 2/4 (50%) 2/4 (50%) 
≤30 years (N=18) 0/16 (0%) 3/16 (18.8%) 3/16 (18.8%) 
≤40 years (N=118) 1/110 (0.9%) 6/110 (5.5%) 7/110 (6.4%) 
≤50 years (N=408) 2/302 (0.7%) 8/302 (2.6%) 10/302 (3.3%) 
Mean age of onset in years (SD) 42.3 (5.5) 30.3 (11.5)  
Family history    
No other family members affected 1/213 (0.5%) 4/213 (1.9%) 5/213 (2.3%) 
1 other family member affected 1/67 (1.5%) 1/67 (1.5%) 2/67 (3.0%) 
2 other family members affected 0/15 (0%) 3/15 (20%) 3/15 (20%) 
3 other family members affected 0/6 (0%) 0/6 (0%) 0/6 (0%) 
4 or more other family members 
affected 
0/1 (0%) 0/1 (0%) 0/1 (0%) 
 353 
PRKN 354 
Of all young-onset patients that were successfully genotyped for PRKN, biallelic pathogenic 355 
PRKN mutations were present in 2.6% (8/302, 95% CI 0.8-4.4%). No PRKN carriers had 356 
homozygous mutations; all mutations were present in compound heterozygous state. 357 
PRKN mutations were present in 20% (3/15, 95% CI 7.0-45.2%) of early onset patients with 2 358 
additional family members affected by Parkinson’s disease. However, there was no significant 359 
difference in the frequency of mutations in early onset patients with a positive family history 360 
(4.2%, 95% CI 0.2-8.4%) and without a family history of Parkinson’s disease (1.9%, 95% 0.05-361 
3.7%), p>0.2 (Fisher’s exact test, OR = 2.3, 95% CI 0.4-12.9). Young-onset patients from large 362 
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Parkinson’s disease families (2 or more additional family members affected) were more likely to 363 
carry a PRKN mutation (13.6%) than early onset patients with 1 or no additional family members 364 
affected (1.6%), p=0.01 (Fisher’s exact test, OR = 8.5, 95% CI 1.2-47.9). 365 
The clinical features of PRKN and PINK1 mutation carriers compared to early-onset non-carriers 366 
are presented in Table 7. PRKN carriers had younger AAO than early onset patients with LRRK2 367 
mutations (42.9 years, 95% CI 39.3-46.6), p=0.009. There was no difference in AAO of PRKN 368 
and PINK1 carriers, p>0.2.   369 
PINK1 370 
Bi-allelic PINK1 mutations were present in 0.7% (2/302, 95% CI 0.2-2.4%) of all screened 371 
young-onset patients. Mutations were present in 1.1% (1/89) of young-onset patients with a 372 
positive family history and 0.5% (1/213) of patients with no family history of Parkinson’s 373 
disease. Mutations were not more frequent with patients with a positive family history, p=0.50 374 
(Fisher’s exact test, OR = 2.4, 95% CI 0.03-189.7). 375 
PRKN and PINK1 mutation carriers had earlier age at study entry and earlier AAO than other 376 
early-onset non-carriers, adjusting for gender and disease duration (Table 7). They also had 377 
longer disease duration than non-carriers, adjusting for age at entry and gender (Table 7). 378 
PRKN and PINK1 mutation carriers also reported more postural problems at diagnosis than non-379 
carriers and tended to report a higher rate of dyskinesias, after adjusting for age at entry, gender, 380 
disease duration and LEDD total, although this did not survive correction for multiple testing.  381 
They also tended to have more gait and freezing problems at assessment, after adjusting for age, 382 
gender, disease duration and LEDD total (p=0.021), although this was not significant after 383 
correction for multiple testing. 384 
Finally, PRKN and PINK1 carriers had better cognition than non-carriers as assessed by the 385 
MoCA, even after adjusting for age, gender, disease duration and LEDD (p=0.007). This appears 386 
to be driven by better performance in the attention subdomain (p=0.004) though one must be 387 
cautious in interpreting the sub-domains as they may be overly simplistic. 388 
 389 
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Genes of unconfirmed pathogenicity for Parkinson’s disease 390 
Patients carrying variants of unconfirmed pathogenicity and risk variants for Parkinson’s disease 391 
identified from exome sequencing are reported in Supplementary Table 4, including variants in 392 
GIGYF2, CHDCHD2. These variants were detected in cases, as previously described, but also 393 
almost all occur in the control population and were not included as pathogenic variants in our 394 
analysis. 395 
We found comparable mutation/variant frequencies in our cohort compared to controls, with the 396 
exception of well-validated risk variants, such as MAPT (Martin et al., 2001; Kwok et al., 2004). 397 
We did not find any patients carrying previously reported mutations in EIF4G1, DNAJC6, 398 
FBXO7 and PLA2G6. Further case-control studies are needed to determine the role of variants in 399 
SNCAIP, UCHL1 and other genes where we found small differences in allele frequencies from 400 
control frequencies, however these variants are unlikely to be pathogenic Mendelian mutations. 401 
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Table 7. Comparison of motor features, fluctuations and non-motor features of early onset patients by recessive gene status (PRKN 402 
and PINK1 carriers vs. non-carriers), excluding patients carrying dominant gene mutations. Scores in the first 4 columns are means 403 
(SD), except for Hoehn and Yahr stage, symptoms present at diagnosis and motor subtype which are shown as N or proportions (%). 404 
Increasing values and increasing betas for motor and non-motor variables are associated with worse symptoms, with the exception of 405 
the MoCA test scores. Increasing values and increasing betas for the MoCA test are associated with better cognition. Cells with only a 406 
single case are indicated with brackets (N=1). 407 
Variable 
Mutation 
negative 
Mutation positive 
(bi-allelic) 
Beta (95% CI) p-valuea 
 N=292 
Total 
N=10 
PRKN 
N=8 
PINK1 
N=2 
Carriers vs. non-carriers 
Age at entry (years) 51.9 (8.1) 50.9 (11.1) 51.8 (12.2) 47.5 (5.9) -7.0 (-10.9, -3.1) 0.001b 
Age at onset (years) 41.1 (6.2) 32.7 (11.5) 30.3 (11.5) 42.3 (5.5) -7.0 (-10.9, -3.1) 0.001b 
Disease duration (years) 10.4 (7.6) 18.2 (14.4) 21.9 (14.4) 5.2 (0.4) 8.9 (5.0, 12.7) <0.001c 
Delay to diagnosis (years) 2.4 (4.2) 4.5 (4.1) 5.2 (4.4) 2.2 (0.1) 2.2 (-0.6, 5.1) 0.123c 
Motor features 
MDS-UPDRS-III total score 26.1 (14.9) 29.0 (24.0) 33.0 (23.6) 5.0 (N=1) -3.3 (-14.4, 7.8) 0.564 
Severity score MDS-UPDRS-
III/years from symptom onset 
4.1 (6.8) 2.4 (2.9) 2.7 (3.1) 0.9 (N=1) -2.5 (-7.7, 2.8) 0.356d 
Upper limb score (max 56) 11.6 (6.7) 13.9 (8.8) 15.3 (8.7) 8.5 (9.2) -1.1 (-5.5, 3.3) 0.621 
Lower limb score (max 32) 6.2 (4.4) 7.7 (5.6) 8.5 (6.0) 4.5 (3.5) -0.1 (-3.1, 3.0) 0.973 
Gait and freezing (max 8) 1.6 (1.5) 3.2 (1.9) 3.6 (1.7) 1.5 (2.2) 1.1 (0.03, 2.1) 0.043 
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Hoehn & Yahr stage     1.8 (0.1, 3.6) 0.049 
0-1.5 (%) 107 (36.7%) 1 (11.1%) 1 (12.5%) 0 (0%)   
2 or 2.5 (%) 140 (48.1%) 4 (44.4%) 3 (37.5%) 1 (100%)   
3+ (%) 44 (15.1%) 4 (44.4%) 4 (50%) 0 (0%)   
Symptoms present at diagnosis 
Tremor 
188/263 
(71.5%) 
7/10  
(70.0%) 
6/8  
(75.0%) 
1/2  
(50.0%) 
-0.9 (-2.4 0.8) 0.275 
Rigidity 
204/255  
(80%) 
8/9 
(88.9%) 
6/7  
(85.7%) 
2/2  
(100%) 
0.7 (-1.2, 3.7) 0.561 
Bradykinesia 
209/257 
(81.3%) 
9/10  
(90.0%) 
7/8  
(87.5%) 
2/2  
(100%) 
15.1 (-55.4, NA) 0.986 
Postural problems 
39/252 
(15.5%) 
6/9  
(66.7%) 
6/7  
(85.7%) 
0/2  
(0%) 
2.3 (0.7, 4.0) 0.005 
Other 
54/229 
(23.6%) 
3/9  
(33.3%) 
3/7  
(42.9%) 
0/2  
(0%) 
0.4 (-1.6, 2.0) 0.684 
Motor subtype (%) 
Tremor dominant 
79/257 
(30.7%) 
2/8  
(25.0%) 
1/6  
(16.7%) 
1/2  
(50%) 
  
Non-tremor dominant (PIGD) 
150/257 
(58.4%) 
6/8  
(75.0%) 
5/6  
(83.3%) 
1/2  
(50%) 
0.4 (-1.4, 2.3) 0.646 
Mixed/ Indeterminate 
28/257 
(10.9%) 
0/8  
(0%) 
0/6  
(0%) 
0/2  
(0%) 
-9.5 (NA, NA) >0.1 
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Motor complications 
MDS-UPDRS-IV total score 5.0 (4.9) 6.2 (5.7) 6.1 (6.3) 6.5 (3.5) 2.3 (-0.5, 4.5) 0.105 
Dyskinesias (presence and 
severity; max 8) 
1.3 (1.9) 2.3 (2.5) 2.1 (2.8) 3.0 (1.4) 1.2 (0.03, 2.3) 0.04 
Fluctuations (max 12) 3.0 (2.9) 3.3 (4.0) 3.4 (4.3) 3.0 (4.2) 0.9 (-0.8, 2.6) 0.309 
Dystonia (max 4) 0.7 (1.1) 0.6 (1.3) 0.6 (1.4) 0.5 (0.7) 0.1 (-0.7, 0.8) 0.891 
Non-motor features 
Cognition - total MoCA score 
(max 30) 
25.6 (3.6) 27.6 (2.2) 27.4 (2.3) 29.0 (N=1) 3.0 (0.8, 5.2) 0.007 
Visuospatial (max 5) 4.4 (1.1) 4.3 (0.5) 4.4 (0.5) 4.0 (N=1) 0.07 (-0.6, 0.8) 0.847 
Naming (max 3) 2.9 (0.3) 2.9 (0.3) 2.9 (0.4) 3.0 (0.0) 0.08 (-1.2, 0.3) 0.441 
Attention (max 6) 5.1 (1.0) 5.6 (0.5) 5.5 (0.5) 6.0 (0.0) 0.9 (0.3, 1.6) 0.004 
Language (max 3) 2.5 (0.7) 2.3 (0.8) 2.4 (0.7) 2.0 (1.4) -0.07 (-0.5, 0.4) 0.767 
Abstraction (max 2) 1.7  (0.6) 1.6 (0.7) 1.6 (0.7) 1.5 (0.7) 0.09 (-0.4, 0.5) 0.704 
Recall (max 5) 3.1 (1.6) 4.2 (1.3) 4.3 (1.4) 4.0 (1.4) 0.9 (-0.2, 2.0) 0.116 
Orientation (max 6) 5.7 (0.7) 6.0 (0.0) 6.0 (0.0) 6.0 (0.0) 0.3 (-0.08, 0.6) 0.131 
LADS Anxiety score (max 18) 6.6 (4.2) 6.1 (2.6) 6.3 (2.8) 5.5 (2.1) -0.4 (-3.3, 2.4) 0.763 
LADS Depression score (max 
18) 
5.8 (3.5) 5.8 (2.3) 6.4 (1.8) 3.5 (3.5) -0.2 (-2.7, 2.4) 0.901 
Sleep disturbance (ESS score) 9.0 (5.7) 8.5 (7.6) 9.5 (8.3) 4.5 (2.1) -0.1 (-4.2, 4.0) 0.961 
REM Sleep Behaviour Disorder 
(RBDSQ) scale score 
5.8 (3.4) 4.3 (2.5) 4.4 (2.8) 4.0 (0.0) -1.2 (-3.6, 1.1) 0.307 
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SD = standard deviation; CI = confidence interval; MDS-UPDRS = Movement Disorder Society Unified Parkinson’s Disease Rating 408 
Scale; PIGD = postural instability gait difficulty; MoCA= Montreal Cognitive Assessment; LADS = Leeds Anxiety and Depression 409 
Scale; ESS= Epworth Sleep Scale; RBDSQ = Rapid Eye Movement Sleep Behaviour Disorder Screening Questionnaire; SCOPA 410 
= SCales for Outcomes in PArkinson's disease. 411 
a P value of clinical features of PRKN and PINK1 carriers together compared to non-carriers, excluding patients with dominant gene 412 
mutations. Adjusting for age at entry, gender, disease duration at entry/assessment and LEDD total, unless otherwise specified. 413 
b Adjusting for gender and disease duration at entry 414 
c Adjusting for gender and age at entry. 415 
d Adjusting for age, gender and LEDD total. 416 
Autonomic function: SCOPA 
total score 
10.8 (6.9) 12.3 (7.4) 9.5 (4.8) 20.5 (9.2) 0.1 (-5.0, 5.3) 0.959 
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Prevalence 417 
In the recent onset cohort (both young-onset and late-onset), the rate of pathogenic mutations 418 
was 1.0% (17/1787). This is a large-scale cohort unselected for AAO, family history and genetic 419 
status. From this, we can estimate the frequency of pathogenic mutations in the general UK 420 
Parkinson’s disease population. The crude prevalence rate of genetic forms of Parkinson’s 421 
disease is 951 per 100 000 (95% CI 892-1013, using the Poisson distribution). Age specific rates 422 
are presented in Table 8. The age-standardised rate of genetic forms of Parkinson’s disease was 423 
708 per 100 000 (95% confidence interval 657-762 per 100 000), standardised to the mid-2016 424 
Great Britain population. This provides an estimate of approximately 725 genetic Parkinson’s 425 
disease patients in a total of 102,403 patients in the UK currently living, using estimates from a 426 
meta-analysis (Wickremaratchi et al., 2009b) and the Office of National Statistics Great Britain 427 
population estimates for mid-2016 (Office for National Statistics, 2017) assuming these genes do 428 
not impact on survival (see Methods). A recent report from Parkinson’s UK using primary care 429 
diagnosis estimated a larger number of Parkinson’s disease patients in the UK (145,519) in 2018 430 
(Parkinson’s UK, 2017). If this figure is more accurate, then the number of genetic Parkinson’s 431 
disease cases would be larger (estimated at 1030).  432 
  433 
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Table 8. Age specific and crude prevalence rate of genetic forms of Parkinson’s disease, using 434 
data from recent onset patients only. 435 
Age Parkinson’s disease 
genetic patients in 
cohort 
Total number of 
Parkinson’s 
disease patients in 
cohort (screened) 
Age specific rates 
per 100,000 
Parkinson’s 
disease patients 
0-29 0 0 0 
30-39 1 11 9091 
40-49 4 58 6897 
50-59 4 219 1826 
60-69 5 728 687 
70-79 2 633 316 
≥80 1 138 725 
Total  17 1787  
Crude prevalence per 
100,000 Parkinson’s 
disease patients 
951 (525-1442)   
Age adjusted prevalence 
per 100,000 Parkinson’s 
disease patients*  
708 (612-713)   
*Age distribution derived from age-specific Parkinson’s disease rates (Wickremaratchi et al., 436 
2009a) applied to the UK mid-2016 population estimates (Office for National Statistics, 2017).  437 
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DISCUSSION 438 
This study represents the largest study examining the rate of known Parkinson’s disease gene 439 
mutations. We report an overall rate of mutations of 1.4% (29/2005), across both young-onset 440 
and late-onset patients. In combination with GBA gene analysis in the same cohort (Malek et al., 441 
2018), our results suggest that up to 10% of Parkinson’s disease patients carry a genetic variant 442 
that could potentially be targeted by new drug therapies. For instance, G2019S and other 443 
mutations in the LRRK2 gene have been shown to increase kinase activity, and LRRK2 kinase 444 
inhibitors that counteract this activity are currently being tested in phase 1 clinical trials as a 445 
potential therapeutic target for Parkinson’s disease (reviewed in (Atashrazm and Dzamko, 2016; 446 
Taymans and Greggio, 2016; Alessi and Sammler, 2018).  447 
The strengths of this study lie in the relatively unbiased, population-based patient ascertainment. 448 
This increases the generalisability of our findings, specifically the prevalence estimates of 449 
Parkinson’s disease patients carrying pathogenic mutations based on the incident recent-onset 450 
cohort. A further strength of this study is inclusion of both early and late-onset patients, where 451 
previous genetic studies have focused on early-onset patients.  452 
Firstly, this has enabled us to more accurately estimate the prevalence of mutations in the general 453 
Parkinson’s disease UK population, assuming there are no survival effects, rather than just in the 454 
subset of early-onset patients. We show clearly that LRRK2 mutations are present at a significant 455 
rate in patients with onset under 50 years (2.2%), and that SNCA mutations are present in 1.5% 456 
of patients with a strong family history of Parkinson’s disease (2 or more additional family 457 
members affected). 458 
Secondly, our findings suggest that there may be other high-risk genes that have not yet been 459 
identified. In particular, further efforts in gene discovery can focus on the substantial proportion 460 
of patients with very early onset or who have a large family history in which no known 461 
pathogenic mutations have been identified. 462 
Thirdly, our findings have implications for genetic testing. Although further work is needed to 463 
confirm some results, our data suggest that LRRK2 mutations are common in young-onset 464 
Parkinson’s disease (2.2%) and should be more regularly tested with appropriate genetic 465 
counselling.  Additionally, our results highlight the importance of systematically screening for 466 
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copy number variants in PRKN, PINK1 and SNCA, as these are common variants and may be 467 
missed with sequencing methods such as exome sequencing. 468 
Finally, we show there are systematic clinical differences between recessive gene mutation 469 
carriers compared to early-onset non-carriers. PRKN and PINK1 carriers have more postural 470 
problems at diagnosis and better cognition than other early onset patients, even after adjusting 471 
for age, disease duration, gender and LEDD.  472 
LRRK2 and SNCA 473 
Mutations in LRRK2 (PARK8, dardarin) were first identified in autosomal dominant, mostly late-474 
onset families with Parkinson’s disease (Funayama et al., 2002; Paisán-Ruíz et al., 2004; 475 
Zimprich et al., 2004). The reported frequency of LRRK2 mutations varies widely; mutations are 476 
more common in familial Parkinson’s disease (5-6%) (Di Fonzo et al., 2005; Nichols et al., 477 
2005) than in sporadic disease (~1%) (Gilks et al., 2005; Hernandez et al., 2005). However the 478 
frequency of mutations also differs according to population, and the G2019S mutation may be 479 
more common in Southern Europe than in Northern Europe (Bonifati, 2007). The rate of 480 
mutations is particularly high in Ashkenazi Jewish (up to 28%) and North African patients (up to 481 
41%) (Lesage et al., 2005, 2006; Ozelius et al., 2006; Williams-Gray et al., 2006; Healy et al., 482 
2008; Puschmann, 2013). We found that LRRK2 mutations were present at a rate of 0.9% 483 
overall, most commonly the G2019S mutation (0.8%). Our findings are comparable with a 484 
previous community-based cohort in the UK (Williams-Gray et al., 2006) and other Caucasian 485 
North American and UK cohorts with estimates between 0.4 and 1.7% (Deng et al., 2005; Farrer 486 
et al., 2005; Hernandez et al., 2005; Zabetian et al., 2005). Our results are also in accordance 487 
with a combined analysis of previous G2019S studies which estimated a mean prevalence of 488 
0.9%, although this was across different populations (Williams-Gray et al., 2006).  489 
R1441C mutations were present in 0.4 % of young-onset and familial patients. This is in keeping 490 
with other studies showing the rarity of LRRK2 R1441C mutations in Caucasian populations, 491 
with previous studies reporting frequencies between 0% and 0.3% (Zabetian et al., 2005; 492 
Pankratz et al., 2006; Möller et al., 2008). To our knowledge, this study is the first to 493 
systematically screen and report on the prevalence of R1441C mutations in early onset and/or 494 
familial Parkinson’s disease in the UK. 495 
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Almost half of our LRRK2 carriers did not report a family history of Parkinson’s disease. 496 
Although the first reports of LRRK2 mutations were in families with multiple affected members, 497 
later studies have shown that a large proportion of LRRK2 carriers do not have other family 498 
members affected by Parkinson’s disease (Gilks et al., 2005; Ozelius et al., 2006). This is likely 499 
due to the reduced penetrance of LRRK2 mutations. The penetrance of both the G2019S and 500 
R1441C mutations is incomplete (24% to 42% up to age 80 for G2019S), strongly age-dependent  501 
and increases in a linear fashion (Clark et al., 2006b; Ozelius et al., 2006; Healy et al., 2008; Lee 502 
et al., 2017). As the population ages, it is likely that increasing numbers of LRRK2 relatives will 503 
develop Parkinson’s disease as a result of LRRK2 mutations, and the prevalence of this form of 504 
Parkinson’s disease will increase in the UK. 505 
As reported in some previous studies (Di Fonzo et al., 2005; Gilks et al., 2005; Kay et al., 2006; 506 
Haugarvoll et al., 2008), we found that LRRK2 carriers presented with a range of AAOs (35 to 507 
79 years). LRRK2 mutations were also more common in young-onset patients (2.2%) than in 508 
late-onset patients (0.5%). However, a combined analysis of all studies in MDSGene showed that 509 
the majority (94%) of LRRK2 carriers have late AAO (Trinh et al., 2018). Our findings do not 510 
support this pattern and further work must be done to clarify this. It may be that studies included 511 
in MDSGene were more likely to screen late-onset patients and not young-onset patients for 512 
LRRK2. This is difficult to assess as MDSGene only compares characteristics of mutation 513 
carriers and not non-carriers. Our findings may have implications for genetic testing where, in 514 
the UK, LRRK2 testing is recommended for late-onset patients with a family history of 515 
Parkinson’s disease. We suggest that LRRK2 should be tested more frequently in young-onset 516 
patients, even those without a family history of Parkinson’s disease, however additional studies 517 
in both young-onset and late-onset patients are needed. 518 
We report two distinct G2019S haplotypes, in keeping with previous studies showing the 519 
mutation has been found in 3 major haplotypes. Haplotype 1 is the most common, present in 520 
European, North American populations of European, Arab and Jewish origin (Goldwurm et al., 521 
2005; Kachergus et al., 2005; Lesage et al., 2006, 2010; Zabetian et al., 2006a). Haplotype 2 has 522 
been reported in North American families of European origin (Zabetian et al., 2006a) and French 523 
families (Lesage et al., 2010). The third haplotype has been found in Japanese patients (Zabetian 524 
et al., 2006b). We show the presence of both haplotype 1 and haplotype 2 in our patients. These 525 
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distinct haplotypes suggest there have been at least 2 independent founding events from which 526 
the G2019S mutation arose, one likely from an ancient Middle Eastern founder (Ozelius et al., 527 
2006; Zabetian et al., 2006a; Lesage et al., 2010).  528 
The R1441C mutation in LRRK2 has also been found on at least two distinct haplotypes. The 529 
first haplotype is reported in a North American family originating from England (Wszolek et al., 530 
1995; Zimprich et al., 2004) and in Flemish-Belgian families (Haugarvoll et al., 2008; 531 
Nuytemans et al., 2008), suggesting a common founder. The second haplotype is present in 532 
Italian, German, Spanish, North American and Iranian patients (Zimprich et al., 2004; 533 
Haugarvoll et al., 2008; Shojaee et al., 2009). These haplotypes suggest that the R1441C 534 
mutation also arose in two independent events/founders, rather than a single ancient founder. Our 535 
constructed R1441C haplotypes were consistent with previous reports but we were unable to 536 
distinguish between the two different haplotypes. 537 
We did not find any differences in motor or non-motor features between LRRK2 carriers and 538 
non-carriers. Several studies and reviews suggest that LRRK2 mutations are associated with a 539 
more benign disease course, less severe clinical symptoms (Nichols et al., 2005), lower risk  of 540 
cognitive impairment and better cognitive performance (Healy et al., 2008; Srivatsal et al., 2015; 541 
Kasten et al., 2017). The MDSGene systematic review also suggested that LRRK2 carriers have a 542 
good response to L-dopa, late AAO and absence of atypical signs (Trinh et al., 2018). However 543 
other studies have not confirmed these findings (Lesage et al., 2005; Haugarvoll et al., 2008; 544 
Healy et al., 2008; Alcalay et al., 2010b; Belarbi et al., 2010; Ben Sassi et al., 2012; Puschmann, 545 
2013; De Rosa et al., 2014; Estanga et al., 2014).  546 
SNCA mutations were first identified in large Parkinson’s disease families with an autosomal 547 
dominant pattern of inheritance (Polymeropoulos et al., 1997; Muenter et al., 1998; Singleton et 548 
al., 2003). SNCA mutations are rare in studies of Caucasian patients (Scott et al., 1999; Berg et 549 
al., 2005; Nuytemans et al., 2009). We found one patient carrying a heterozygous duplication, 550 
comprising 1.5% of patients reporting 2 or more additional family members affected by 551 
Parkinson’s disease. This is in line with previous studies reporting a mutation prevalence of 1.7% 552 
to 5.8% in familial Parkinson’s disease patients (Farrer et al., 2004; Ibáñez et al., 2004; Nishioka 553 
et al., 2009; Bozi et al., 2014).  554 
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It has previously been reported that SNCA mutation carriers have more frequent and more severe 555 
dementia, rapid progression, hallucinations and autonomic dysfunction (Muenter et al., 1998; 556 
Farrer et al., 2004; Fuchs et al., 2007; Ahn et al., 2008; Nishioka et al., 2009; Puschmann, 2013; 557 
Bonifati, 2014; Kasten et al., 2017; Schneider and Alcalay, 2017). SNCA triplications cause a 558 
more severe phenotype while duplications tend to cause more ‘typical’ Parkinson’s disease 559 
(Chartier-Harlin et al., 2004; Ibáñez et al., 2004; Hernandez et al., 2016). We were not able to 560 
compare clinical features this in our cohort due to the rarity of SNCA mutations. 561 
Our cohort represents the largest UK-based series of LRRK2 and SNCA carriers and non-carriers 562 
identified from the same unselected population, including both early and late onset patients. In 563 
line with many previous studies, our findings suggest that Parkinson’s disease caused by LRRK2 564 
mutations duplications is clinically indistinguishable from sporadic disease. 565 
Young-onset Parkinson’s disease 566 
We found pathogenic mutations in 6.3% (19/302) of young-onset patients, including mutations in 567 
both dominant and recessive genes. These are comparable to the frequencies previously reported 568 
in other young-onset cohorts (Alcalay et al., 2010a; Kilarski et al., 2012; Kim and Alcalay, 569 
2017). In accordance with previous studies (Alcalay et al., 2010a; Marder et al., 2010), we show 570 
that mutations were more common in patients with earlier onset.  571 
We identified compound heterozygous PRKN mutations in 2.6% of young-onset patients. While 572 
this is lower than other prevalence estimates in Caucasian populations (Abbas et al., 1999; 573 
Lücking et al., 2000; Lohmann et al., 2003; Periquet et al., 2003), our findings are in accordance 574 
with a previous UK community-based study which found that PRKN mutations accounted for 575 
3.7% of patients with onset under 45 years (Kilarski et al., 2012). 576 
We also identified 3% patients carrying single heterozygous pathogenic mutations in PRKN and 577 
PINK1. Our frequency of single heterozygous carriers is similar to what has been reported in 578 
other studies, although these include varying methods for identifying copy number variants 579 
(Klein et al., 2007; Marder et al., 2010).  580 
Previous studies suggest that PRKN mutations are more common in familial patients (Alcalay et 581 
al., 2010a). We found a trend for PRKN mutations to be more common in familial (4.2%) than in 582 
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sporadic patients (1.9%), although not significantly different. However, 20% of patients with 2 583 
additional family members affected carried PRKN mutations. 584 
We found evidence for a shared haplotype for the P113Xfs mutation in five carriers across three 585 
markers spanning 242 kB. Our analysis does not include genotyping of microsatellite markers 586 
which are needed for more detailed haplotype analysis. However our findings are consistent with 587 
previous evidence showing that point mutations have shared haplotypes and may originate from 588 
a common founder (Farrer et al., 2001; Periquet et al., 2001). 589 
PINK1 mutation carriers were present in 0.7% of young-onset patients. This is comparable to the 590 
rate reported in a previous community-based study (Kilarski et al., 2012). Mutations are more 591 
common in Asian and Italian patients (Hatano et al., 2004; Valente et al., 2004; Bonifati et al., 592 
2005; Li et al., 2005; Tan et al., 2006), reflecting population-specific allele frequencies. Our 593 
findings are consistent with the low prevalence estimates in Northern Europe and North 594 
American patients (Healy et al., 2004; Rogaeva et al., 2004). However contrary to previous 595 
reports (Kilarski et al., 2012), we did not find that mutations were more frequent in patients with 596 
a family history of Parkinson’s disease (1.1%) compared to sporadic patients (0.5%). This may 597 
be due to the small number of PINK1 carriers in our cohort. 598 
After controlling for age and disease duration, we found that PRKN and PINK1 carriers had 599 
earlier AAO, reported more postural symptoms at diagnosis and had better cognition compared 600 
to other young-onset patients. This is consistent with previous studies showing that PRKN and 601 
PINK1 mutations are generally associated with slower disease progression and less cognitive 602 
impairment (Valente et al., 2001, 2004, Lohmann et al., 2003, 2012; Bonifati et al., 2005; Tan et 603 
al., 2006; Alcalay et al., 2014; Bonifati, 2014; Kasten et al., 2017; Kim and Alcalay, 2017). 604 
Some studies have suggested that atypical features, such as dystonia, and psychiatric symptoms 605 
may be more common in PINK1 and PRKN carriers (Bonifati et al., 2005; Kasten et al., 2017; 606 
Koros et al., 2017), however we did not find evidence to support this; there is also substantial 607 
variability of the frequency of these symptoms in previous reports (Kasten et al., 2017). Our 608 
findings are in line with a recent MDSGene systematic review, which suggested that recessive 609 
gene mutation carriers have less common cognitive decline, good treatment response and 610 
otherwise clinically typical disease (Kasten et al., 2018). While a few conflicting reports suggest 611 
there are no clinical differences between PRKN carriers and non-carriers (Lohmann et al., 2009), 612 
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our findings in a large population-based study definitively show that there are clinical differences 613 
between mutation carriers and non-carriers. This may be associated with the lack of Lewy body 614 
pathology in the brain at post-mortem (Takahashi H, Ohama E, 1994; Mori et al., 1998), 615 
although there are small numbers of PRKN cases with pathological data and there is variability in 616 
findings (Farrer et al., 2001; Schneider and Alcalay, 2017). 617 
Limitations 618 
Our cohort was predominantly Caucasian and no pathogenic mutations were identified in non-619 
Caucasian groups. Therefore, the estimated rate of mutations has limited application in other 620 
populations. Further large-scale studies are needed to establish mutation prevalence in other 621 
ethnic groups. Our results are also limited by the lack of complete screening; exome sequencing, 622 
MLPA and PRKN and PINK1 sequencing of all patients was not feasible due to cost limitations 623 
and the size of the cohort. Recessive gene mutations are rare in patients with older onset (Alcalay 624 
et al., 2010a; Kilarski et al., 2012), however PRKN mutations have been identified in late-onset 625 
patients with onset up to 78 years (Foroud et al., 2003; Klein et al., 2003). Therefore, there may 626 
have been a small number of mutation carriers that were not detected with our screening 627 
methods. Our data therefore represents a minimal estimate of the frequency of genetic mutations 628 
and true numbers may be slightly higher. Our genetic rates are based on both incident and 629 
prevalent cases. We have assumed that survival and hence prevalence is not influenced by these 630 
genes but if some genes e.g. PRKN and PINK1 are associated with better survival then we may 631 
have under-estimated the number of cases in the general population.  632 
A further limitation is that, while this is a large cohort study, the rarity of pathogenic mutations 633 
means that our group difference comparisons may be under-powered to detect modest 634 
phenotypic differences. Finally, our cohort is likely to still have some biases in it, given we did 635 
not undertake a rigorous community based study collecting all cases of the condition. 636 
Conclusions 637 
We show that Mendelian gene mutations are a rare but significant cause of Parkinson’s disease. 638 
Patients with PRKN and PINK1 mutations differ from other early onset patients in cognition and 639 
postural symptoms. In combination with estimates of GBA mutation prevalence, this large-scale, 640 
relatively unbiased study suggests that up to 10% of Parkinson’s disease patients carry known 641 
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genetic variants that could be targeted by new drug therapies in clinical trials and future 642 
treatment.  643 
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